These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15549345)

  • 1. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?
    Riedel M; Strassnig M; Müller N; Zwack P; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):143-8. PubMed ID: 15549345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL].
    Gasquet I; Flandre P; Heurtebize N; Deal C; Perrin E; Chartier F; Fourrier-Réglat A
    Encephale; 2009 Feb; 35(1):25-31. PubMed ID: 19250990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients.
    Zhang XY; Chen DC; Xiu MH; Yang FD; Haile CN; Kosten TA; Kosten TR
    J Clin Psychiatry; 2012 Jul; 73(7):1025-33. PubMed ID: 22901352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do clinical trial participants compare to other patients with schizophrenia?
    Barnett PG; Scott JY; Rosenheck RA;
    Schizophr Res; 2011 Aug; 130(1-3):34-9. PubMed ID: 21514794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic reassessment and treatment response in schizophrenia.
    Honer WG; Smith GN; MacEwan GW; Kopala L; Altman S; Yorkston N; Ehmann TS; Smith A; Lang M
    J Clin Psychiatry; 1994 Dec; 55(12):528-32. PubMed ID: 7814346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender-related clinical differences in older patients with schizophrenia.
    Lindamer LA; Lohr JB; Harris MJ; McAdams LA; Jeste DV
    J Clin Psychiatry; 1999 Jan; 60(1):61-7; quiz 68-9. PubMed ID: 10074884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
    Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
    Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments.
    Sato T; Bottlender R; Schröter A; Möller HJ
    Schizophr Res; 2004 Apr; 67(2-3):175-83. PubMed ID: 14984876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.